Primary cutaneous diffuse large B-cell lymphoma, leg type: A report of 4 cases with literature review

Ya'ni Li, Huaqing Wang, Lihua Qiu, Zhengzi Qian, Huilai Zhang, Kai Fu

Research output: Contribution to journalArticle

Abstract

Objective: To explore the morbidity, clinical features, metastasis, treatment, and prognostic factors of primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL). Methods: The clinical records of 4 patients treated at the Tianjin Medical University Cancer Hospital from January 1970 to September 2010, including gender, age, site of cutaneous involvement (leg or non-leg, extent of cutaneous involvement, lactate dehydrogenase (LDH, β2-microglobulin (β2-MG), B symptoms, relapse (yes or no), involvement of lymph nodes and organs, treatment and survival were retrospectively reviewed. Results: From January 1970 to September 2010, the incidence of PCLBCL, leg type in Tianjin was 4.8/10 million. Of the 4 patients, 2 were males and 2 were females, aged from 2 to 55 years. The median age was 29 years. The cutaneous nodules or tumors were common clinical features. Of the 4 patients, 3 involved the legs and 1 was non-leg, 3 were localized involvements, and 1 was disseminated involvement. Lymph nodes (1 case) were involved in follow-up visit. Three patients underwent a surgical operation combined with chemotherapy and only 1 underwent only the surgical operation. CHOP or CHOP-like chemotherapy was predominant. The median survival time was only 30.5 months. The mean survival time of the males and females was 25 and 219.5 months, respectively. The mean survival time in terms of the site of cutaneous involvement (leg and non-leg) were 162 and 3 months, respectively. The mean survival times in term of the extent of cutaneous involvement (localized and disseminated) were 158 and 14 months, respectively. The mean survival time in terms of relapse (yes, no) were 30.5 and 214 months, respectively. Conclusion: PCLBCL, leg type is a rare extranodal lymphoma. The clinical manifestations are atypical. The diagnosis of PCLBCL, leg type is confirmed by histopathologic examination. Surgical operation combined with chemotherapy could improve the prognosis, but the prognosis is still poor. The prognosis is probably associated with gender, site of cutaneous involvement, extent of cutaneous involvement, and relapse.

Original languageEnglish (US)
Pages (from-to)1124-1126
Number of pages3
JournalChinese Journal of Clinical Oncology
Volume38
Issue number18
DOIs
StatePublished - Sep 30 2011

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Leg
Skin
Survival Rate
Recurrence
Drug Therapy
Lymph Nodes
Cancer Care Facilities
Tissue Survival
Lymphoma
Neoplasm Metastasis
Morbidity
Survival
Incidence
Therapeutics

Keywords

  • Clinical features
  • Incidence
  • Leg type
  • Primary cutaneous diffuse large B-cell lymphoma
  • Prognosis
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Primary cutaneous diffuse large B-cell lymphoma, leg type : A report of 4 cases with literature review. / Li, Ya'ni; Wang, Huaqing; Qiu, Lihua; Qian, Zhengzi; Zhang, Huilai; Fu, Kai.

In: Chinese Journal of Clinical Oncology, Vol. 38, No. 18, 30.09.2011, p. 1124-1126.

Research output: Contribution to journalArticle

Li, Ya'ni ; Wang, Huaqing ; Qiu, Lihua ; Qian, Zhengzi ; Zhang, Huilai ; Fu, Kai. / Primary cutaneous diffuse large B-cell lymphoma, leg type : A report of 4 cases with literature review. In: Chinese Journal of Clinical Oncology. 2011 ; Vol. 38, No. 18. pp. 1124-1126.
@article{2a1a407d23cd49f1b7667192b6a45f5b,
title = "Primary cutaneous diffuse large B-cell lymphoma, leg type: A report of 4 cases with literature review",
abstract = "Objective: To explore the morbidity, clinical features, metastasis, treatment, and prognostic factors of primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL). Methods: The clinical records of 4 patients treated at the Tianjin Medical University Cancer Hospital from January 1970 to September 2010, including gender, age, site of cutaneous involvement (leg or non-leg, extent of cutaneous involvement, lactate dehydrogenase (LDH, β2-microglobulin (β2-MG), B symptoms, relapse (yes or no), involvement of lymph nodes and organs, treatment and survival were retrospectively reviewed. Results: From January 1970 to September 2010, the incidence of PCLBCL, leg type in Tianjin was 4.8/10 million. Of the 4 patients, 2 were males and 2 were females, aged from 2 to 55 years. The median age was 29 years. The cutaneous nodules or tumors were common clinical features. Of the 4 patients, 3 involved the legs and 1 was non-leg, 3 were localized involvements, and 1 was disseminated involvement. Lymph nodes (1 case) were involved in follow-up visit. Three patients underwent a surgical operation combined with chemotherapy and only 1 underwent only the surgical operation. CHOP or CHOP-like chemotherapy was predominant. The median survival time was only 30.5 months. The mean survival time of the males and females was 25 and 219.5 months, respectively. The mean survival time in terms of the site of cutaneous involvement (leg and non-leg) were 162 and 3 months, respectively. The mean survival times in term of the extent of cutaneous involvement (localized and disseminated) were 158 and 14 months, respectively. The mean survival time in terms of relapse (yes, no) were 30.5 and 214 months, respectively. Conclusion: PCLBCL, leg type is a rare extranodal lymphoma. The clinical manifestations are atypical. The diagnosis of PCLBCL, leg type is confirmed by histopathologic examination. Surgical operation combined with chemotherapy could improve the prognosis, but the prognosis is still poor. The prognosis is probably associated with gender, site of cutaneous involvement, extent of cutaneous involvement, and relapse.",
keywords = "Clinical features, Incidence, Leg type, Primary cutaneous diffuse large B-cell lymphoma, Prognosis, Treatment",
author = "Ya'ni Li and Huaqing Wang and Lihua Qiu and Zhengzi Qian and Huilai Zhang and Kai Fu",
year = "2011",
month = "9",
day = "30",
doi = "10.3969/j.issn.1000-8179.2011.18.018",
language = "English (US)",
volume = "38",
pages = "1124--1126",
journal = "Chinese Journal of Clinical Oncology",
issn = "1672-7118",
publisher = "China Anti-Cancer Association",
number = "18",

}

TY - JOUR

T1 - Primary cutaneous diffuse large B-cell lymphoma, leg type

T2 - A report of 4 cases with literature review

AU - Li, Ya'ni

AU - Wang, Huaqing

AU - Qiu, Lihua

AU - Qian, Zhengzi

AU - Zhang, Huilai

AU - Fu, Kai

PY - 2011/9/30

Y1 - 2011/9/30

N2 - Objective: To explore the morbidity, clinical features, metastasis, treatment, and prognostic factors of primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL). Methods: The clinical records of 4 patients treated at the Tianjin Medical University Cancer Hospital from January 1970 to September 2010, including gender, age, site of cutaneous involvement (leg or non-leg, extent of cutaneous involvement, lactate dehydrogenase (LDH, β2-microglobulin (β2-MG), B symptoms, relapse (yes or no), involvement of lymph nodes and organs, treatment and survival were retrospectively reviewed. Results: From January 1970 to September 2010, the incidence of PCLBCL, leg type in Tianjin was 4.8/10 million. Of the 4 patients, 2 were males and 2 were females, aged from 2 to 55 years. The median age was 29 years. The cutaneous nodules or tumors were common clinical features. Of the 4 patients, 3 involved the legs and 1 was non-leg, 3 were localized involvements, and 1 was disseminated involvement. Lymph nodes (1 case) were involved in follow-up visit. Three patients underwent a surgical operation combined with chemotherapy and only 1 underwent only the surgical operation. CHOP or CHOP-like chemotherapy was predominant. The median survival time was only 30.5 months. The mean survival time of the males and females was 25 and 219.5 months, respectively. The mean survival time in terms of the site of cutaneous involvement (leg and non-leg) were 162 and 3 months, respectively. The mean survival times in term of the extent of cutaneous involvement (localized and disseminated) were 158 and 14 months, respectively. The mean survival time in terms of relapse (yes, no) were 30.5 and 214 months, respectively. Conclusion: PCLBCL, leg type is a rare extranodal lymphoma. The clinical manifestations are atypical. The diagnosis of PCLBCL, leg type is confirmed by histopathologic examination. Surgical operation combined with chemotherapy could improve the prognosis, but the prognosis is still poor. The prognosis is probably associated with gender, site of cutaneous involvement, extent of cutaneous involvement, and relapse.

AB - Objective: To explore the morbidity, clinical features, metastasis, treatment, and prognostic factors of primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL). Methods: The clinical records of 4 patients treated at the Tianjin Medical University Cancer Hospital from January 1970 to September 2010, including gender, age, site of cutaneous involvement (leg or non-leg, extent of cutaneous involvement, lactate dehydrogenase (LDH, β2-microglobulin (β2-MG), B symptoms, relapse (yes or no), involvement of lymph nodes and organs, treatment and survival were retrospectively reviewed. Results: From January 1970 to September 2010, the incidence of PCLBCL, leg type in Tianjin was 4.8/10 million. Of the 4 patients, 2 were males and 2 were females, aged from 2 to 55 years. The median age was 29 years. The cutaneous nodules or tumors were common clinical features. Of the 4 patients, 3 involved the legs and 1 was non-leg, 3 were localized involvements, and 1 was disseminated involvement. Lymph nodes (1 case) were involved in follow-up visit. Three patients underwent a surgical operation combined with chemotherapy and only 1 underwent only the surgical operation. CHOP or CHOP-like chemotherapy was predominant. The median survival time was only 30.5 months. The mean survival time of the males and females was 25 and 219.5 months, respectively. The mean survival time in terms of the site of cutaneous involvement (leg and non-leg) were 162 and 3 months, respectively. The mean survival times in term of the extent of cutaneous involvement (localized and disseminated) were 158 and 14 months, respectively. The mean survival time in terms of relapse (yes, no) were 30.5 and 214 months, respectively. Conclusion: PCLBCL, leg type is a rare extranodal lymphoma. The clinical manifestations are atypical. The diagnosis of PCLBCL, leg type is confirmed by histopathologic examination. Surgical operation combined with chemotherapy could improve the prognosis, but the prognosis is still poor. The prognosis is probably associated with gender, site of cutaneous involvement, extent of cutaneous involvement, and relapse.

KW - Clinical features

KW - Incidence

KW - Leg type

KW - Primary cutaneous diffuse large B-cell lymphoma

KW - Prognosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=80855128154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80855128154&partnerID=8YFLogxK

U2 - 10.3969/j.issn.1000-8179.2011.18.018

DO - 10.3969/j.issn.1000-8179.2011.18.018

M3 - Article

AN - SCOPUS:80855128154

VL - 38

SP - 1124

EP - 1126

JO - Chinese Journal of Clinical Oncology

JF - Chinese Journal of Clinical Oncology

SN - 1672-7118

IS - 18

ER -